Organization
Daegu Catholic University Medical Center, Daegu, Korea, Republic Of
1 abstract
Abstract
A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY COMPARING SB2, AN INFLIXIMAB BIOSIMILAR, TO THE INFLIXIMAB REFERENCE PRODUCT (REMICADE®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY Org: Daegu Catholic University Medical Center, Daegu, Korea, Republic Of, Clinical Center Banja Luka, Banja Luka, Bosnia and Herzegovina, Medica Pro Familia, Gdynia, Poland, MHAT “Dr. Ivan Seliminski”, AD, Sliven, Bulgaria, MEDICAL PLUS s.r.o, Uherske Hradiste, Czech Republic,